JPMorgan analyst Robbie Marcus lowered the firm’s price target on Insulet (PODD) to $340 from $415 and keeps an Overweight rating on the shares. The firm updated the company’s model post earnings.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet price target lowered to $340 from $380 at Citi
- Insulet price target lowered to $435 from $450 at Canaccord
- Insulet price target raised to $286 from $274 at Barclays
- Insulet: Strong Q4 Execution and Encouraging 2026 Outlook Offset by Valuation and Competitive Pressures, Justifying Hold Rating
- Insulet: Sustained Growth Runway and Underappreciated Long‑Term Upside Support Buy Rating